SCHEMBL7168397

SCHEMBL7168397

CSc1ccc(Oc2ccccc2C2CCCN2C(=O)C(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 1/20 0.41
▸ HSP90AB1 P08238 1/20 0.41
▸ RIPK1 Q13546 2/20 0.41
▸ SLC6A4 P31645 3/20 0.40
▸ MAPT P10636 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ GCK P35557 3/20 0.38
▸ HCRTR1 O43613 3/20 0.37
▸ HCRTR2 O43614 3/20 0.37
▸ PPIB P23284 1/20 0.37
▸ PPID Q08752 1/20 0.37
▸ PPIG Q13427 1/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ ROCK2 O75116 1/20 0.37
▸ FFAR1 O14842 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6049323 0.89 HSP90AA1 (0.40) HSP90AA1HSP90AB1RIPK1GCKHCRTR1
SCHEMBL6049177 0.86 HSP90AA1 (0.41) HSP90AA1HSP90AB1RIPK1MAPTGCK
Hydrochloric Acid SCHEMBL6049195 0.78 SLC6A4 (0.45) SLC6A4MAPTSLC6A2SLC6A3HTR2A
SCHEMBL23064471 0.73 PPID (0.48) HSP90AA1HSP90AB1RIPK1PPIBPPID
SCHEMBL28537451 0.73 PPID (0.48) HSP90AA1HSP90AB1RIPK1PPIBPPID
SCHEMBL28535096 0.71 RIPK1 (0.46) HSP90AA1HSP90AB1RIPK1HSD11B1
SCHEMBL28535098 0.71 RIPK1 (0.46) HSP90AA1HSP90AB1RIPK1HSD11B1
SCHEMBL2645563 0.71 GCK (0.44) RIPK1SLC6A4GCKHSD11B1
SCHEMBL31525016 0.70 RIPK1 (0.45) HSP90AA1HSP90AB1RIPK1
SCHEMBL1576663 0.70 RIPK1 (0.73) HSP90AA1HSP90AB1RIPK1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6630504-B2 Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, sexual dysfunction PFIZER INC. 2003-10-07 — — US disclosed
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs PFIZER INC. 2002-12-05 — — US disclosed
EP-1184372-A1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) Pfizer Limited (GB) 2002-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs CRHR1, NR3C1, HTR6 HSP90AA1 2431/4885HSP90AB1 2039/4885RIPK1 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback